Skip to content

Acute Cardiovascular Effects of an L-Theanine and L-Glycine Beverage in Postmenopausal Women at Rest

The Effects of a Single Dose containing L-Theanine and L-Glycine (The-Gly) amino acids on blood pressure, heart rate, heart rate variability, and skin microvascular function in Postmenopausal Women

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12625001335482
Enrollment
30
Registered
2025-12-01
Start date
2026-01-12
Completion date
2026-07-15
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study is a pilot randomised, placebo-controlled clinical trial to determine the effects of a single dose of two amino acids L-theanine and L-Glycine (The-Gly) on resting cardiovascular responses in postmenopausal women. This study involves two visits, one for the measurement of baseline parameters and second visit for the intervention and 60 minutes and 120 minutes follow up.

Interventions

The study is a randomized, double-blind, placebo-controlled, parallel trial consisting of two visits. The first visit for baseline assessments and the second for the supplementation intervention. At the first visit, participants will fast overnight for 10 hours before capillary blood (~100 µL) is collected to measure cardiometabolic risk biomarkers, including fasting glucose, HbA1c, total cholesterol, triglycerides, and HDL-C. Following blood collection, participants will receive breakfast, and

The study is a randomized, double-blind, placebo-controlled, parallel trial consisting of two visits. The first visit for baseline assessments and the second for the supplementation intervention. At the first visit, participants will fast overnight for 10 hours before capillary blood (~100 µL) is collected to measure cardiometabolic risk biomarkers, including fasting glucose, HbA1c, total cholesterol, triglycerides, and HDL-C. Following blood collection, participants will receive breakfast, and baseline anthropometric measurements (height, weight, waist, and hip circumferences) and physical performance tests (grip strength, gait speed, chair-rise ability, and submaximal exercise test) will be conducted. The second visit, occurring within one week, involves a 15-minute supine rest followed by baseline measurements of resting heart rate (HR), heart rate variability (HRV), blood pressure (BP), and skin microvascular function. The aim of the skin microvascular test is to measure the reactive hyperaemia response, providing insights into vascular reactivity and endothelial function of the microcirculation. Participants will then consume either the active supplement containing 5 g glycine, 200 mg L-theanine amino acids, 3.3 g sweetener, 10mg watermelon flavour, and 1.5 g citric acid, or a colour, flavour, and Odor matched placebo dissolved in 300 mL of water and consumed within 5 minutes. Adherence to the intervention was ensured by direct observation. After the supplement or placebo was provided, research team monitored participants as they drank the entire beverage, confirming that the full dose was consumed as intended. Any issues during intake were recorded immediately. Post-intervention measurements of HR, HRV, BP, and skin microvascular function will be repeated at 60 and 120 minutes. Dietary intake will be assessed using a 24-hour recall for the day prior to the second visit, along with a brief recall of breakfast on the day of supplementation.

Sponsors

University of Canberra
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
45 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Female participants aged 45 years and above who have experienced natural menopause. Participants will be in general good health, willing to comply with all the study procedures.

Exclusion criteria

Participants will be excluded from the study if they have experienced menopause due to hysterectomy (surgical), medical conditions, or treatments, and if they are on hormonal replacement therapy.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026